υπέρ TAVI κατά
No conflict of interest
more than 200,000 implants have been done in 65 countries. TAVI is a common procedure with reduced complications, better case selection, and refined tools. PCR 2015 Έξυπνη διατύπωση Δεν αναφέρεται σαν καλύτερη θεραπεία κ.λ.π.
We've totally screwed up," said VW America boss Michael Horn Έξυπνη διατύπωση In November, VW also said it had found "irregularities" in tests to measure carbon dioxide emissions levels that could affect about 800,000 cars in Europe - including petrol vehicles.
Public Release: 19-May-2015 EuroPCR 2015: TAVI, safe and effective as surgical valves at 2 years in lower risk patients Transcatheter valve implantation is comparable to surgery for a composite endpoint of all-cause death, stroke, or MI EuroPCR (NOTION) trial
Μετά από 22 χρόνια η TAVI απευθύνεται όχι σε αυτούς που είχε «φτωχά» αποτελέσματα η χειρουργική AVR
Ισχνές μελέτες??????????? Μάλλον η AVR αποτελεί αξίωμα
CDU: Οι βουλευτές μπορούν να διατηρούν θέσεις σε πολυεθνικές εταιρίες
As I said before, reimbursement is an important factor in the penetration of TAVI in Europe. In the UK, the National Institute for Health and Clinical Excellence approved TAVI for inoperable patients in July 2011. In Germany, TAVI is part of a diagnosis-related group (DRG) and is reimbursed at 34,080; in France it is part of a DRG valued at 28,477, but it is restricted to 33 centres. Austria will include TAVI in a DRG of 27,227 in January. In Italy, there is regional reimbursement and, in Lombardia, for example, the DRG pays 25,308 for a TAVI procedure. In Spain, it is according to hospital budget. Switzerland is set to include TAVI in a DRG in January 2012, but the tariff is still under discussion.
Μείωση της επιβίωσης λόγω της αορτικής ανεπάρκειας Cardiac surgeon shot at Brigham and Women's Hospital dies Published January 21, 2015FoxNews.com
Predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation: an analysis from the multicentre German TAVI registry. Heart. 2014 Aug;100(16):1250-6. doi: 10.1136/heartjnl-2013-305385. Epub 2014 Jun 3. At 1 year, 61 patients (31%) with more-than-mild post-tavi AR had died.
Exclusion criteria I MI < 1 month before treatment Congenital unicuspid or bicuspid aortic valve or non-calcified aortic valve Mixed aortic valve disease Cardiac procedure resulting in a permanent implant performed within 30 days of the procedure or within 6 months if drug eluting coronary stent implanted Severe mitral insufficiency Leukopenia, acute anemia, thrombocytopenia, bleeding diathesis or coagulopathy Untreated clinically significant coronary artery disease Hemodynamic or respiratory instability within 30 days of screening Need for emergency surgery Hypertrophic cardiomyopathy
Exclusion criteria II Severe ventricular dysfunction ECHO evidence of intracardiac mass, thrombus or vegetation Active peptic ulcer or active GI bleeding within 3 months prior to procedure A known contraindication to anticoagulation or inability to be anticoagulated for the procedure Native aortic annulus size <18mm or >25mm CVA, TIA or cluster within 6 months of the procedure Renal insufficiency and/or end-stage renal disease requiring dialysis at the time of screening
Exclusion criteria III Estimated life expectancy <12 months due to non-cardiac conditions Significant aortic disease, such as abdominal aortic or thoracic aneurysm, marked tortuosity, aortic arch atheroma Ileofemoral vessel characteristics that would preclude safe placement of the introducer sheath such as severe obstructive calcification, severe tortuosity or vessel s size Participating in an investigational drug or another device study Active endocarditis or other active infections within 6 months of the procedure Bulky calcified aortic valve leaflets in close proximity to coronary ostia
TAVR is not recommended in patients with comorbidities that would preclude an expected benefit from correction of AS.
Transcatheter Aortic Valve Implantation 10-year Anniversary Eur Heart J. 2012;33(19):2388-2398. Since TAVI has been shown to be superior to standard medical therapy and non-inferior to SAVR and is increasingly being used in current practice, the incremental costs and costeffectiveness of this therapy warrant evaluation.
In the PARTNER IB trial, the mean cost for TF TAVI was $42 806 which accumulated to $78 542 for the initial hospitalization and $106 076 at 1 year. [36] Compared with medical therapy, TAVI was ~$52 455 (95% CI, $40 635 $64 275) more expensive at 1 year
Εάν όλες οι βαλβίδες στην Ελλάδα TAVI 68.000.000 Εάν όλες SAVR 25.500.000 διαφορά 42.500.000 Χρήματα που αντιστοιχούν ετησίως με τους μισθούς 1.328 Διευθυντών Καρδιολόγων
Τι ξοδεύουμε σήμερα για τις TAVI στην Ελλάδα Περίπου 8.000.000 δηλαδή μισθούς 215 καθηγητών πανεπιστημίου πρώτης βαθμίδας Οι δανειστές στην Αθήνα: Σκληρό παζάρι για τα ισοδύναμα
We are paying a lot [with TAVI] for quality of life, and it's the quality of the end of life